Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The epidemic of type 2 diabetes is an enormous public health problem in all parts of the world, with 366 million cases by 2030. Chronic inflammation has been postulated to play a role in the pathogenesis of type 2 diabetes. High levels of adiponectin and inflammatory biomarkers are known as a new risk factor for diabetes. There is accumulating evidence suggesting that altered vitamin D and calcium homeostasis affect the development of type 2 diabetes, but it is still unclear whether that effects are through reducing the level of adipocytokines and inflammatory biomarkers or not. This study has been designed to evaluate the effects of vitamin D and calcium supplementations alone and in combination on inflammatory biomarkers and adypocytokines in type 2 diabetic patients.
This study is a single masked, controlled randomized trial with period of 8 weeks. 120 diabetic patients who met the inclusion criteria will enroll in this study. Subjects will randomly assign in to four groups. Randomization will be achieved by permuted blocks with stratification by age, sex, BMI, type of diabetes and dose of medication. Group1 will receive 50000 IU of vitamin D3 per week plus calcium placebo, group2 will received 1000 mg of calcium carbonate per day plus vitamin D placebo, group 3 will receive 50000 IU of vitamin D3 plus 100 of mg calcium carbonate per day and group four will receive calcium and vitamin D placebos. Total cholesterol, HDL, LDL, serum triglyceride, serum glucose, serum insulin, HbA1C, leptin, adiponectin and inflammatory biomarkers such as TNF-alpha, IL-6 and high sensitivity C reactive protein (hs-CRP) will be determine by taking blood samples at the baseline and at the end of intervention. Systolic and diastolic blood pressure and anthropometric measurements (height, weight, hip and waist circumferences) will be measured at the baseline and after 8 weeks of intervention. 3 dietary records and 3 physical activity records will be taken at 2,4 and 6 week of intervention to make sure that all subjects maintain their usual diet and physical activity during intervention.
| Condition | Intervention |
|---|---|
|
Nutritional and Metabolic Disease |
Dietary Supplement: vitamin D3 supplement Dietary Supplement: calcium supplement Dietary Supplement: vitamin D3 and calcium supplement Dietary Supplement: placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients |
- change in inflammatory biomarkers from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]including:IL-6, TNF-alpha, hs-CRP
- change in adipocytokines from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]including: adiponectin and leptin
- change in weight (Kg) from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- change in lipid profile from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]including: LDL, HDL, total cholesterol, TG
- change in serum Glucose from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- change in height (Cms) from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- change in hip circumference (Cms) from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- change in waist circumference (Cms) from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- change in serum Insulin from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- change in HbA1C from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- change in blood pressure from baseline at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 120 |
| Study Start Date: | February 2012 |
| Estimated Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: vitamin D3
vitamin D3 supplement 50000 IU vitamin D3 per week
|
Dietary Supplement: vitamin D3 supplement
Other Name: cholecalciferol
|
|
Experimental: calcium supplement
calcium supplement 1000 mg calcium carbonate daily
|
Dietary Supplement: calcium supplement
Other Name: calcium carbonate
|
|
Experimental: vitamin D and calcium supplement
vitamin D3 and calcium supplementation 50000 IU vitamin D3 per week and 1000 mg calcium carbonate daily
|
Dietary Supplement: vitamin D3 and calcium supplement
Other Name: cholecalciferol and calcium carbonate
|
|
Placebo Comparator: placebo
placebo
|
Dietary Supplement: placebo |
Eligibility| Ages Eligible for Study: | 30 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- more than 30 years old
- have no history of renal failure, cancer, liver diseases, thyroid diseases or any other inflammatory diseases
- have no allergy
- do not use any tobacco products
- not using corticosteroids
- not consuming any kinds of vitamin D or calcium supplement
- have not more than 4 kilograms weight change during last 3 months
Exclusion Criteria:
- pregnancy
- insulin dependent diabetes
Contacts and Locations| Contact: marjan tabesh, MS | 00989131664159 | tabesh@hlth.mui.ac.ir |
| Iran, Islamic Republic of | |
| Medical School of Isfahan | Recruiting |
| Isfahan, Iran, Islamic Republic of | |
| Contact: esmaillzadeh, PhD esmaillzadeh@hlth.mui.ac.ir | |
| Principal Investigator: marjan tabesh, MS | |
More Information
No publications provided
| Responsible Party: | Marjan Tabesh, Director, Isfahan University of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT01662193 History of Changes |
| Other Study ID Numbers: | 190136 |
| Study First Received: | July 29, 2012 |
| Last Updated: | August 10, 2012 |
| Health Authority: | Iran:medical school of isfahan |
Keywords provided by Isfahan University of Medical Sciences:
|
Cholecalciferol Calciol vitamin D3 Diabetes Mellitus Diabetes Mellitus Type 2 |
glucose metabolism disorders ergocalciferol calcium adipicytokines inflammatory biomarkers |
Additional relevant MeSH terms:
|
Metabolic Diseases Calcium, Dietary Cholecalciferol Vitamin D Ergocalciferols Calcium Carbonate Vitamins |
Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Antacids Molecular Mechanisms of Pharmacological Action Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 23, 2013